

HERCULES TECHNOLOGY GROWTH CAPITAL INC  
Form 8-K  
October 22, 2009

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 20, 2009**

**Hercules Technology Growth Capital, Inc.**

(Exact name of registrant as specified in its charter)

**Maryland**

**814-00702**

**74-3113410**

(State or other jurisdiction (Commission File No.) (I.R.S. Employer

of incorporation)

Identification No.)

400 Hamilton Ave., Suite 310

Palo Alto, CA

94301

(Name and Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(650) 289-3060**

Not Applicable

(Former name or  
address, if changed  
since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 Other Events**

On October 20, 2009, Hercules Technology Growth Capital, Inc. (the “Company”) issued a press release announcing certain developments with respect to the business of six of its portfolio companies and also announced that the Company continues to work diligently through certain credit concerns with respect to certain portfolio companies.

Gomez, Inc. entered into a definitive agreement in October 2009 to be acquired by Compuware Corporation in a \$295 million cash transaction. The acquisition is anticipated to close in November 2009. Assuming the transaction is completed, the Company expects to realize gross estimated proceeds from the sale of its warrants of approximately \$2.0 million. There can be no assurance that this transaction will be completed.

Two of the Company’s portfolio companies entered into development and licensing agreements. Merrimack Pharmaceuticals, Inc. entered into a worldwide collaboration and licensing agreement in October 2009 with Sanofi-aventis and Paratek Pharmaceuticals, Inc. entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement in October 2009 with Novartis AG.

Labopharm Inc. recently addressed certain FDA concerns with respect to a drug manufacturing process and its subsidiary completed a distribution and supply agreement for a certain drug formulation. QuatRx Pharmaceuticals Company finished a Phase III efficacy and safety program for a particular product. Finally, Ancestry.com filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock.

The text of this press release is included as an exhibit to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release dated October 20, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HERCULES  
TECHNOLOGY  
GROWTH CAPITAL,  
INC.

October 21, 2009

/s/ Scott Harvey  
Scott Harvey  
Chief Legal Officer

EXHIBIT INDEX

**Exhibit No.**    **Description of Exhibits**

99.1              Press Release dated October 20, 2009